Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies
Season 2, Episode 45, Jul 30, 02:06 PM
Share
Subscribe
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Vinay Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen Bagley, MD, MSCE; and Angela Waanders, MD, MPH, MS; discuss advancements in targeted therapies to treat adult and pediatric low- and high-grade gliomas.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
Episode Description
In this podcast, experts Vinay Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen Bagley, MD, MSCE; and Angela Waanders, MD, MPH, MS; discuss advancements in targeted therapies to treat adult and pediatric low- and high-grade gliomas.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate recent classification criteria and diagnostic strategies for identification of adult and pediatric patients with glioma
- Incorporate genetic and molecular information to accurately classify gliomas and develop personalized treatment plans
- Appraise recent developments in targeted, immunotherapeutic, and other novel therapeutic approaches, including potential implications of investigational approaches in the care of patients with gliomas
- Determine strategies to integrate targeted and immunotherapeutic approaches and assess the potential implications of emerging novel approaches in the management of pediatric gliomas
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from Chimerix, Inc; Day One Biopharmaceuticals; and Servier Pharmaceuticals LLC.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 6432
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
This activity is supported by educational grants from Chimerix, Inc; Day One Biopharmaceuticals; and Servier Pharmaceuticals LLC.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 6432
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair:
Vinay K. Puduvalli, MD
Professor and Chair, Department of Neuro-Oncology
Co-Director, Cancer Neuroscience Program
Co-Director, NeuroHealth Initiative
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory Board: Boehringer Ingelheim, Guidepoint, Novocure, Orbus Therapeutics, Servier, Tango Therapeutics, Telix Pharmaceuticals; Honorarium: Boehringer Ingelheim, Guidepoint, Novocure, Orbus Therapeutics, Servier, Tango Therapeutics, Telix Pharmaceuticals
Faculty:
Manmeet Ahluwalia, MD, MBA
Professor of Translational Medicine
Herbert Wertheim College of Medicine, Florida International University
Fernandez Family Foundation Endowed Chair in Cancer Research
Chief of Medical Oncology
Chief Scientific Officer and Deputy Director
Miami Cancer Institute, Baptist Health South Florida
Miami, FL
Disclosures: Consultant: AnHeart Therapeutics, Apollomics, Bayer, Menarini Ricerche, TherAguix, Varian Medical Systems, ViewRay, Xoft
Stephen J. Bagley, MD, MSCE
Assistant Professor of Medicine and Neurosurgery
Section Chief
Neuro-Oncology Section
Division of Hematology/Oncology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
Disclosures: Advisor: Modifi Bio, Servier, Telix; Researcher: GSK, Incyte, Kite (a Gilead company), Lilly, Novocure
Angela Waanders, MD, MPH, MS
Associate Professor of Pediatrics (Hematology, Oncology, and Stem Cell Transplantation)
Section Head, Neuro-Oncology
Director, Precision Medicine Oncology
Gus Foundation Chair in Neuro-Oncology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures: Ad Hoc Consultant: Day One, Ipsen; Chair: Alexion; Member: Day One; Scientific Advisory Board: Alexion, Day One; Selumetinib Registry: Alexion
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
Chair:
Vinay K. Puduvalli, MD
Professor and Chair, Department of Neuro-Oncology
Co-Director, Cancer Neuroscience Program
Co-Director, NeuroHealth Initiative
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory Board: Boehringer Ingelheim, Guidepoint, Novocure, Orbus Therapeutics, Servier, Tango Therapeutics, Telix Pharmaceuticals; Honorarium: Boehringer Ingelheim, Guidepoint, Novocure, Orbus Therapeutics, Servier, Tango Therapeutics, Telix Pharmaceuticals
Faculty:
Manmeet Ahluwalia, MD, MBA
Professor of Translational Medicine
Herbert Wertheim College of Medicine, Florida International University
Fernandez Family Foundation Endowed Chair in Cancer Research
Chief of Medical Oncology
Chief Scientific Officer and Deputy Director
Miami Cancer Institute, Baptist Health South Florida
Miami, FL
Disclosures: Consultant: AnHeart Therapeutics, Apollomics, Bayer, Menarini Ricerche, TherAguix, Varian Medical Systems, ViewRay, Xoft
Stephen J. Bagley, MD, MSCE
Assistant Professor of Medicine and Neurosurgery
Section Chief
Neuro-Oncology Section
Division of Hematology/Oncology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
Disclosures: Advisor: Modifi Bio, Servier, Telix; Researcher: GSK, Incyte, Kite (a Gilead company), Lilly, Novocure
Angela Waanders, MD, MPH, MS
Associate Professor of Pediatrics (Hematology, Oncology, and Stem Cell Transplantation)
Section Head, Neuro-Oncology
Director, Precision Medicine Oncology
Gus Foundation Chair in Neuro-Oncology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures: Ad Hoc Consultant: Day One, Ipsen; Chair: Alexion; Member: Day One; Scientific Advisory Board: Alexion, Day One; Selumetinib Registry: Alexion
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on advancements in targeted therapy in adult and pediatric high- and low-grade gliomas, go https://www.gotoper.com/annual-oncology-meeting-25-glioma-activity.
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.